Longboard Pharmaceuticals, Inc. Common Stock
LBPH
LBPH was delisted on the 29th of November, 2024.
50 hedge funds and large institutions have $107M invested in Longboard Pharmaceuticals, Inc. Common Stock in 2023 Q2 according to their latest regulatory filings, with 27 funds opening new positions, 14 increasing their positions, 6 reducing their positions, and 2 closing their positions.
1,250% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 2
133% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 6
107% more capital invested
Capital invested by funds: $51.5M → $107M (+$55.3M)
100% more funds holding
Funds holding: 25 → 50 (+25)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$5.39M |
| 2 |
JP Morgan Chase
New York
|
+$4.29M |
| 3 |
IC
Ikarian Capital
Dallas,
Texas
|
+$3.82M |
| 4 |
PHP
Parkman Healthcare Partners
Stamford,
Connecticut
|
+$2.59M |
| 5 |
State Street
Boston,
Massachusetts
|
+$2.23M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$4.24M |
| 2 |
Millennium Management
New York
|
-$4.12M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$3.22M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.51M |
| 5 |
PM
Prosight Management
Dallas,
Texas
|
-$1.25M |
LBPH Hedge Fund Activity: Q2 2023 in Review
50 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Longboard Pharmaceuticals, Inc. Common Stock (LBPH) for Q2 2023, worth a combined $107M — up 107% from $51.5M a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new LBPH positions and 2 closed out — a net gain of 25 holders — while 14 added to existing stakes and 6 trimmed.
The largest buyer was BlackRock, adding an estimated $5.39M. The largest seller was Farallon Capital Management, cutting an estimated $4.24M.
- 50 institutional investors held Longboard Pharmaceuticals, Inc. Common Stock (LBPH) as of Q2 2023, up from 25 in Q1 2023.
- Funds reported $107M of Longboard Pharmaceuticals, Inc. Common Stock stock for Q2 2023, up 107% quarter-over-quarter.
- 27 funds opened new Longboard Pharmaceuticals, Inc. Common Stock positions in Q2 2023 and 2 closed out, a net change of +25 holders.
- The largest Longboard Pharmaceuticals, Inc. Common Stock buyer in Q2 2023 was BlackRock, an estimated $5.39M added.
- The largest Longboard Pharmaceuticals, Inc. Common Stock seller in Q2 2023 was Farallon Capital Management, an estimated $4.24M sold.
Based on aggregated 13F filings for Q2 2023.